AGP Executive Report
Last update: 6 hours agoBMS–Hengrui Deal: Bristol Myers Squibb and China’s Hengrui Pharma signed a global collaboration and licensing pact worth up to $15.2 billion, covering 13 early-stage oncology, hematology and immunology programs, with Hengrui leading early clinical development and both sides splitting rights by territory; the deal is expected to close in Q3 2026. Macao Health Access: Macau’s MOP700 medical e-vouchers are set to expand into Guangdong clinics/outpatient departments from June 1, while the Health Bureau reported Macao’s first imported malaria case of the year (a mainland man returning from Nigeria, in serious condition). Chronic Disease Focus: The Health Bureau says about 89% of registered hypertension patients received treatment in 2024, supported by 337 blood-pressure check points. Cross-border Convenience: The Social Security Fund held briefings in Hengqin on the revised two-tier social security law, aiming to make cross-border benefits feel “without distance.” Local Public Health Watch: Macau also reported a Legionnaires’ disease case involving an 83-year-old resident, bringing the year’s total to six.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
